New 3-Week radiation combo could tame pancreatic cancer

NCT ID NCT03902600

Ongoing Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a 3-week course of radiation (using photons or protons) combined with chemotherapy for people with pancreatic cancer that hasn't spread. The goal is to see if this shorter treatment is safe and effective, either before surgery or as the main therapy. Researchers will also check if levels of pancreatic cancer DNA in the blood can help predict how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy (photon and proton) combined with chemotherapy
What this could lead to: If successful, this could offer a shorter, more effective radiation schedule for pancreatic cancer with fewer side effects, and show that blood DNA levels help predict treatment response.
What could go wrong: This is a mid-stage trial with only 103 participants, so results may not apply to all patients. The radiation dose is higher than standard, which could increase gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.